University of Groningen

Neonatal capsaicin causes compensatory adjustments to energy homeostasis in rats

van de Wall, E. H. E. M.; Wielinga, P. Y.; Strubbe, J. H.; van Dijk, G.

Published in:
Physiology and Behavior

DOI:
[10.1016/j.physbeh.2006.03.018](https://doi.org/10.1016/j.physbeh.2006.03.018)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2006

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

van de Wall, E. H. E. M., Wielinga, P. Y., Strubbe, J. H., & van Dijk, G. (2006). Neonatal capsaicin causes compensatory adjustments to energy homeostasis in rats. *Physiology and Behavior*, 89(1), 115-121.
<https://doi.org/10.1016/j.physbeh.2006.03.018>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Neonatal capsaicin causes compensatory adjustments to energy homeostasis in rats

E.H.E.M. van de Wall, P.Y. Wielinga, J.H. Strubbe, G. van Dijk *

Department of Animal Physiology, Unit Neuroendocrinology, University of Groningen, PO box 14, 9750 AA Haren, The Netherlands

Received 2 December 2005; received in revised form 14 March 2006; accepted 15 March 2006

Abstract

Several mechanisms involved in ingestive behavior and neuroendocrine activity rely on vagal afferent neuronal signaling. Seemingly contradictory to this idea are observations that vagal afferent neuronal ablation by neonatal capsaicin (CAP) treatment has relatively small effects on glucose homeostasis and long-term regulation of energy balance. It may be proposed that humoral endocrine factors and/or their sensitivities compensate for the loss of vagal afferent information, particularly when subjects face disturbances in ambient fuel levels. Therefore, male adult rats neonatally treated with CAP or with the vehicle (VEH) underwent intravenous glucose tolerance tests (IVGTTs) during which blood fuel levels, and circulating adipose, pancreatic, and adrenal hormones were assessed. CAP rats displayed similar hyperglycemia as VEH rats, but with markedly reduced plasma insulin and corticosterone responses. These results indicate that CAP rats have increased insulin sensitivity during hyperglycemic episodes, and lower plasma levels of corticosterone in CAP rats relative to VEH rats could underlie this effect. After the IVGTT, CAP rats had increased plasma adiponectin and reduced plasma resistin levels, and these alterations in adipose hormones might be relevant for post-ingestive metabolic processes. In a second experiment, anorexigenic efficacies of cholecystokinin and leptin were assessed. While VEH rats, but not CAP rats, responded with reduced food intake to i.p. injected cholecystokinin, only CAP rats responded to i.v. infused leptin with a reduction in food intake. It is concluded that reduced HPA axis activity and/or increased leptin signaling could underlie compensations in fuel handling and energy balance following CAP treatment.

© 2006 Elsevier Inc. All rights reserved.

Keywords: IVGTT; leptin; adiponectin; corticosterone; FFA; melanocortin; CCK; vagal afferents

1. Introduction

Energy homeostasis is maintained by an array of biochemical and physiological mechanisms that help to ensure the constancy of the internal environment under varying nutritional conditions and energy demands. An important component of the underlying regulatory processes consists of peripheral information regarding the energetic status which is conveyed via vagal neuronal afferents to the CNS. In turn, these signals are relayed in CNS neuronal networks where they play a role in the sensation of hunger and satiety as well as in the regulation of neuroendocrine control of energy homeostasis [1].

With the advent of capsaicin (CAP)—a pungent ingredient of red peppers which selectively destroys primary C-afferents and

small myelinated A δ -afferents (for review see [2,3])—a pharmacological tool became available to study the effect of ablation of vagal primary afferents on regulation of energy balance. CAP-treated animals have disturbances in short-term satiety signaling and do not respond to cholecystokinin (CCK) with reduced food intake [4–6]. However, CAP-treated rats have similar daily food intake [7], similar or even lower body weight [8] and improved glucose homeostatic control [17] compared to controls. Furthermore, deafferentated animals have a long-term decrease in white adipose tissue mass [9] and are more resistant to ageing-associated obesity [10]. Finally, CAP treatment results in increased whole body insulin sensitivity [11] and a lower degree of ageing-associated insulin resistance [10]. These observations indicate that CAP-treated animals are able, or even have improved capability, to maintain body weight and energy homeostasis, despite the fact that they lack seemingly important information transmitted via vagal afferents to the CNS. To date, the underlying mechanisms are poorly understood.

* Corresponding author. Tel.: +31 50 3632116; fax: +31 50 3632331.

E-mail address: gertjan.van.dijk@rug.nl (G. van Dijk).

Another class of peripheral factors highly relevant to the regulation of ingestive behavior, energy homeostasis, and body weight maintenance consists of endocrine/hormonal factors which are released into the blood stream and affect enzymatic/endocrine processes and metabolic fluxes in various peripheral organs and tissues [12]. In addition, most of these factors can enter the CNS where they alter the activity of neuronal circuitry involved in ingestive behavior, neuroendocrine outflow and metabolism [12]. One hypothesis pertinent to the observations that CAP-treated rats are able to maintain body and energy homeostasis might be that vagal afferent ablation is compensated by these redundant endocrine factors involved in the regulation of energy homeostasis and ingestive behavior. To investigate this hypothesis, the concentration of blood fuels (i.e., plasma glucose and free fatty acids) and circulating hormones involved in blood glucose regulation and ingestive behavior (i.e., insulin, leptin, adiponectin, resistin and corticosterone) were investigated in overnight fasted rats that were neonatally treated with CAP or with the vehicle (VEH). In addition, the changes in these blood parameters were assessed during and after an intravenous glucose tolerance test (IVGTT). In a second experiment, anorexigenic efficacies of CCK, leptin, and the synthetic melanocortin (MC) receptor-agonist, melanotan II [13], were assessed in CAP and VEH rats. The latter study was performed since the MC4 receptor is implicated in the leptin signaling cascade [14].

2. Materials and methods

2.1. Animals and housing

Twenty-eight male Wistar rats from the breeding facility of our university were used and housed in climate-controlled rooms ($22 \pm 2^\circ\text{C}$) under a 12-h:12-h light–dark cycle (lights on at 8:00 a.m.). Food and water were ad libitum available, unless mentioned otherwise. All experiments were checked and approved by the Local Ethics Committee of our university.

2.2. Capsaicin treatment

Rats were treated neonatally with CAP (8-methyl-*N*-valeryl-6-nonenamide, 50 mg/kg; Sigma Chemical, The Netherlands) at the age of day 2 ($n=14$) by subcutaneous (s.c.) injection. This was done under 100% O_2 conditions to avoid hypoxia. CAP was dissolved in vehicle consisting of 10% ethanol (10%) and 5% cremophore–0.9% sodium chloride solution (90%). As a control, VEH solution was injected s.c. ($n=14$). Each animal was given the same volume of 50 μl based on an average weight of the pups of 8 g. At injection, both groups did not differ significantly in body weight (CAP 8.84 ± 0.20 g; VEH 8.32 ± 0.23 g). CAP-treated and VEH-treated pups grew up separately—to avoid selective mother care—in litters of 5–9 pups, in the proportion of 5–7 male on 2 females (untreated). After weaning at the age of 23 days, rats were individually housed in clear Plexiglas cages ($25 \times 25 \times 30$ cm) with a bedding of sawdust. Following treatments, body weights were assessed at days 34, 58, and thereafter, every 10 days until experiments. An eye-wipe response (0.1% capsaicin solution) was done at the

age of 3 months in order to test the effectiveness of the CAP treatment. As opposed to the VEH controls, none of the neonatally CAP-treated animals responded to the test and all animals were therefore included in the experiment.

2.3. Surgery

After the eye-wipe test, 16 animals were implanted with double heart catheters in the left and right jugular veins according to techniques described by Steffens [15]. An additional 12 animals were provided with heart catheters only in the right jugular vein according to the same techniques. Surgery was performed under anaesthesia with isoflurane/ $\text{N}_2\text{O}/\text{O}_2$. Fynadine (0.01 ml/100 g body weight) was given s.c. as post-surgical analgesia. Animals had at least 2 weeks of recovery before the start of experiments.

2.4. Intravenous glucose tolerance test (IVGTT)

Body weights did not differ significantly between both groups (CAP: 403 ± 7.7 ; VEH: 410 ± 10.9). Overnight food-deprived CAP ($n=8$) and VEH-treated rats were subjected to an IVGTT, which was performed in the light period between 12:00 a.m. and 1:00 p.m. At least half an hour before the start of the IVGTT, rats were connected with their indwelling cannulae to blood sampling (right jugular catheter) and infusion (left jugular catheter) tubing. These tubes extended out of the rats' cages, which allowed stress-free blood sampling and/or intravenous infusion. After taking two basal blood samples at $t=-11$ and $t=-1$ min, a glucose solution (15% dissolved in sterile demineralized water) was infused over a 30-min period at a rate of 15 mg/min (450 mg total). Additional samples were taken at $t=1, 3, 5, 10, 15, 20, 25, 30, 40, 50$ min in order to assess blood glucose and plasma insulin. In general, samples consisted of 0.2 ml whole blood for assessment of blood glucose (50 μl) and plasma insulin (50 μl) levels. At $t=-11$, $t=30$, and $t=50$, an additional 0.2 ml of blood was taken for determination of plasma levels of adiponectin (3 μl), leptin (30 μl), resistin (30 μl), corticosterone (10 μl), and free fatty acids (FFAs, 10 μl). Blood and plasma samples were stored at -20°C until analysis. Blood glucose levels were measured by the ferricyanide method of Hoffman; plasma levels of insulin, adiponectin, leptin, resistin and corticosterone were measured by commercial radioimmunoassay kits (Linco Research, Nucli lab, The Netherlands), and plasma levels of FFAs were assessed with a NEFA C enzymatic kit (WAKO Chemicals GmbH, Germany).

2.5. Anorexigenic efficacies of CCK, leptin and melanotan-II

In another group of CAP- ($n=4-6$) and VEH- ($n=4-6$)-treated rats, the anorexigenic efficacies of CCK, leptin, and the synthetic melanocortin 3/4 receptor agonist, melanotan-II were assessed. Therefore, rats' food hoppers were removed from their home cages 2 h before lights off. In a counterbalanced design, and with 5 days elapsing between successive experiments, rats were i.v. infused between 30 and 15 min before lights off solutions containing leptin (70 $\mu\text{g}/250$ μl saline, Calbiochem,

Fig. 1. Effects of neonatal capsaicin (CAP) treatment and vehicle (VEH) treatment on body weight gain of male Wistar rats.

Germany; this dose corresponds to 164 $\mu\text{g/kg}$ in control animals and 160 $\mu\text{g/kg}$ in CAP-treated rats), melanotan-II (50 $\mu\text{g}/250 \mu\text{l}$ saline, Sigma Chemical, The Netherlands; this dose corresponds to 118 $\mu\text{g/kg}$ in control animals and 114 $\mu\text{g/kg}$ in CAP-treated rats), or with saline (250 μl) only. After all treatments, food hoppers were returned to the cages at lights off, and cumulative food intake was assessed at 1, 2, and 4 h in the dark phase. In other tests, but under similar experimental conditions, these animals were i.p. injected with saline (250 μl) or with saline containing CCK (4 $\mu\text{g/kg}$ Sigma Chemical, The Netherlands) just before the dark phase. Because vagal afferent ab-

Fig. 2. Blood glucose and plasma insulin levels before, during, and after an IVGTT consisting of a 15% glucose infusion infused over 30 min in adult male Wistar rats, which were neonatally treated with capsaicin (CAP) or vehicle (VEH). * and **, $p < 0.05$ and $p < 0.01$, respectively.

lation is known to impair peripheral actions of CCK on ingestive behavior [4–6], this latter comparison was performed as a positive control for CAP treatment. Seven animals of each group were decapitated (non-fasted) at the end of the experiment and weights of fat pads (retroperitoneal and epididymal fat) and liver as well as basal plasma leptin levels were assessed.

2.6. Statistical analysis

Data are presented $\pm$ the standard error of the mean (S.E.M.). Analysis of variance (ANOVA) with repeated measurements was performed for statistical evaluation with time (sampling points) as within-subject factor and group (CAP or VEH) as between-subject factor. Post hoc pairwise comparisons (LSD

Fig. 3. Circulating adipocyte factors leptin, adiponectin and resistin before, during, and after an IVGTT consisting of a 15% glucose infusion infused over 30 min in adult male Wistar rats, which were neonatally treated with capsaicin (CAP) or vehicle (VEH). * $p < 0.05$.

Fig. 4. Plasma corticosterone levels and free fatty acid (FFA) levels before, during, and after an IVGTT consisting of a 15% glucose infusion infused over 30 min in adult male Wistar rats, which were neonatally treated with capsaicin (CAP) or vehicle (VEH). * and **, $p < 0.05$ and 0.01 , respectively.

test) were done based on estimated marginal means. Statistical testing was performed from sampling point -11 or -1 min till sampling point 30 min at the end of the glucose infusion. One-sided Student's t -test was used for unpaired observations. A value of $p \leq 0.05$ was considered significant for all tests.

3. Results

Body weights of CAP and VEH rats are shown in Fig. 1. Although CAP rats appeared slightly lighter than VEH rats, there were no significant differences over time. In VEH and CAP rats, epididymal fat pad weights (8.9 ± 0.8 g and 7.5 ± 0.9 g, respectively), retroperitoneal fat pad weights (2.6 ± 0.3 g and 2.0 ± 0.5 g, respectively), liver weights (16.5 ± 0.7 g and 15.5 ± 1.4 g, respectively), and plasma leptin levels (3.95 ± 0.79 ng/ml and 3.54 ± 1.12 ng/ml, respectively) did not differ significantly.

3.1. Intravenous glucose tolerance test (IVGTT)

Fig. 2 shows the changes in blood glucose and plasma insulin levels before, during, and after the 30-min intravenous glucose infusion. ANOVA with repeated measurements revealed significant effects of time on plasma levels of insulin and glucose ($F_{8,112} = 40.6$, $p < 0.001$ and $F_{8,80} = 66.7$, $p < 0.05$, respectively). There was no significant time $\times$ group interaction for insulin ($F_{8,112} = 1.7$, $p = 0.11$) or glucose ($F_{8,80} = 0.46$, $p = 0.88$). There

was a significant group effect on plasma insulin levels during glucose infusion ($F_{1,14} = 4.9$, $p < 0.05$), but blood glucose levels did not differ significantly between CAP and VEH ($F_{1,10} = 0.46$, $p = 0.51$). This difference in insulin response was particularly clear at $t = 1$ min, which is considered as the first-phase insulin response (CAP = 4.55 ± 0.43 , VEH = 7.03 ± 0.71 , $p < 0.01$).

Fig. 3 shows changes in the plasma concentrations of the adipocyte hormones leptin, adiponectin, and resistin at $t = -1$, 30 and 50 min. At baseline ($t = -1$), none of the assessed levels of these hormones differed among CAP and VEH, and these levels were not different during glucose infusion either. However, after cessation of glucose infusion ($t = 50$ min), the plasma adiponectin level of CAP rats was significantly higher ($p < 0.05$) than that of VEH rats. In contrast, plasma resistin was

Fig. 5. Effects of cholecystokinin (CCK), leptin and melanotan-II (MTII) on food intake in adult male Wistar rats which were neonatally treated with capsaicin (CAP) or vehicle (VEH). *, **, and ***, $p < 0.05$, 0.01 , and 0.001 , respectively.

lower at $t=50$ min in CAP rats relative to VEH controls ($p<0.05$). Plasma levels of leptin were not different in CAP and VEH rats ($F_{1,13}=2.12$, $p=0.17$). Fig. 4 shows the changes observed in plasma concentrations of corticosterone and FFAs. In VEH controls, plasma levels of corticosterone were increased as a result of glucose infusion, but this effect was not observed in CAP rats. Thus, plasma levels of corticosterone in CAP rats were significantly lower ($p<0.01$) than in VEH rats at $t=30$ min. During glucose infusion, plasma levels of FFAs were reduced in both groups relative to baseline. After infusion, there was a partial rebound in VEH rats, but not in the CAP rats. Thus, plasma FFAs were significantly reduced at $t=50$ min ($p<0.05$) in CAP rats relative to VEH controls.

3.2. Anorexigenic efficacies of CCK, leptin and melanotan-II

Fig. 5 shows the effect of i.v. infusion of leptin and MTII relative to saline treatment, and of i.p. injection of CCK relative to saline treatment on food intake. CCK caused a significant reduction in food intake relative to saline treatment in VEH controls ($p<0.05$) during the first hour of the dark phase, and a tendency to reduce food intake during the second hour. These effects were not observed in CAP rats. In contrast, i.v. leptin infusion appeared to be effective over the first 2 h in the dark phase only in CAP rats ($p<0.05$), but not in VEH rats. This effect was mostly due to the fact that the leptin-treated CAP rats did not have food intake during the second hour, whereas food intake over the first hour was similar as in VEH rats. Finally, i.v. infusion of MTII was equally effective in reducing food intake over the full 4-h period in CAP and VEH rats. Interestingly, MTII was more effective to reduce food intake over the first hour in VEH rats than in CAP rats ($p<0.01$).

4. Discussion

Vagal afferent ablation in rats by neonatal capsaicin (CAP) treatment has been shown in other studies to be ineffective [8], or in some cases even preventive [10] of causing disturbances in energy balance and glucose homeostasis. Since vagal afferents are thought to serve important homeostatic functions [16], the present study was designed to investigate the hypothesis that neonatal CAP treatment results in compensatory adjustments by redundant endocrine factors involved in the regulation of energy balance and glucose homeostasis. Important for consideration of the data in the present study is that body weights of our CAP and VEH rats were not different, nor were there any overt differences in weights of organs and tissues relevant to nutrient balance. Basal (i.e., non-fasted) plasma leptin levels did not differ between CAP and VEH animals either.

Consistent with a seemingly normal regulation of energy balance was the observation that CAP- and VEH-treated rats had indistinguishable fasting levels of adipocyte (i.e., leptin, adiponectin, and resistin), pancreatic (i.e., insulin) and adrenal (i.e., corticosterone) hormones; i.e., all factors known to correlate strongly with changes in energy balance. A different picture emerged when viewing the data obtained with the IVGTT. Thus, whereas the IVGTT caused similar increments in blood glucose

levels in CAP and VEH rats, the plasma insulin response was markedly reduced in CAP rats relative to that in VEH-treated controls. These data confirm our previous findings in non-fasted CAP and VEH rats challenged with different glucose loads, yielding similar dose-dependent elevations in blood glucose levels, but with much lower plasma insulin responses in CAP rats relative to those seen in VEH rats [17]. While the reduced glucose-mediated insulin response in CAP rats might be the result of absence of tonic activation of vagal afferents by gut hormones [17,18], one implication of these findings is that CAP rats are more insulin-sensitive than VEH controls. This idea is in agreement with the findings of Koopmans et al. [11], who observed increased whole body insulin action in CAP rats under euglycemic hyperinsulinemic clamp conditions.

Humoral factors that stimulate insulin-dependent glucose uptake are leptin and adiponectin [19] in a variety of tissues, whereas corticosterone [20], resistin [21] and FFAs [22,23] have the opposite effects. Among these, only the plasma level of corticosterone was significantly different in CAP and VEH rats at the end of the IVGTT. More specifically, the IVGTT led to an increase in the plasma corticosterone level in the VEH rats, but this effect was not observed in CAP rats. Although we have not performed a full analysis of plasma corticosterone levels over the course of the IVGTT, it might be possible that this reduced plasma corticosterone level underlies the increased insulin sensitivity in CAP rats. A lower corticosterone response in CAP rats was previously observed by Koopmans et al. [11], and, together with the data in the present study, this suggests a role for vagal afferents and/or sensory nerves in the activation of the HPA axis during hyperglycemia. It seems likely that vagal afferents normally convey stimulatory actions of gut hormones, such as CCK, on HPA axis activity [24]. These effects might be amplified under hyperglycemic condition, analogous to the mechanism underlying stimulated insulin secretion [18]. Such a dependency on hyperglycemia would be consistent with the finding in the present study that the difference in plasma corticosterone levels in CAP and VEH rats disappeared as rats regained normoglycemia after the IVGTT. After cessation of the IVGTT, blood glucose, plasma insulin and corticosterone levels returned to normal, but a higher plasma adiponectin and lower resistin levels in CAP rats relative to VEH controls was found at this stage. It might be possible that the transiently different plasma corticosterone levels in CAP and VEH rats contributed to these effects [25,26] but additional or more important factors are not ruled out. While it is unlikely that the changes in adiponectin and resistin levels contributed to the differences in glucose-to-insulin indexes during the preceding IVGTT, they might have a major impact on successive excursions of blood glucose or on the metabolic consequences of these. In fact, the lower level of plasma FFA in CAP rats after the IVGTT might be a direct consequence of elevated plasma adiponectin levels and/or reduced plasma resistin levels in these animals. Indeed, adiponectin has been shown to stimulate muscle fatty acid transporter [27] and to increase oxidation of FFA in skeletal muscle [28]. This would result in accelerated FFA clearance from the blood. A link between circulating FFAs and resistin is less clear, but correlation analysis in mice suggests an interaction

between high circulating resistin levels with hyperlipidemia, as well as with obesity and insulin resistance [29]. Our results are in agreement with Spiridonov and Vorobeveva [30], who also reports decreased FFA levels after neonatal treatment. Typically, higher levels of FFA are associated with disturbances in glucose homeostatic mechanisms [31] and this could mean that decreased levels of FFA contribute to the enhanced glucose disposal in CAP rats in following fuel excursions.

Despite the observed changes in adiponectin, resistin, and corticosterone responses, there was no effect of the IVGTT on the plasma levels of leptin, nor were there any differences between the plasma leptin levels of CAP and VEH rats at baseline. One idea that we addressed was the possibility that CAP treatment increases leptin signaling. Whereas injection of CCK, dosed to cause a reduction in food intake in VEH rats, did not have any effect in CAP rats in the present study (and confirming previous reports by [4–6], we observed that peripherally infused leptin caused a reduction in food intake in the CAP rats, but failed to do so in VEH rats. These effects were particularly pronounced over the second hour of the dark phase; i.e., after the rats had eaten their first meals. Important for consideration of the effects of peripherally elevated levels of leptin is that these can be signaled directly in the CNS (i.e., through increased transport of leptin across the blood–brain barrier) and additionally via vagal afferent fibers [32–34]. Since CAP rats lack a substantial part of their vagal afferent innervation, yet have an increased sensitivity to leptin with respect to food intake modulation, it is likely that leptin's enhanced anorexigenic actions are mediated via interaction with CNS pathways. Actions of leptin on ingestive behavior are mediated through neural networks among which the brain melanocortin (MC) system might be most relevant [35]. Since CAP rats had a slightly lower anorexigenic response to the brain-specific melanocortin receptor agonist, melanotan-II, than VEH rats (presumably due to compensatory actions), the difference between leptin sensitivity in VEH and CAP rats is either located upstream from brain MC receptors or requires changes in neuronal circuitry parallel to the brain MC system.

Provided that the augmented anorexigenic effects of leptin are coincided with the altered neuroendocrine and metabolic actions of leptin [12], this could possibly have contributed to the lower plasma levels of corticosterone [36] and resistin [37] and the elevated plasma level of adiponectin [38] in CAP rats. On the other hand, a lower level of circulating glucocorticoids might have contributed to the increased leptin signaling by hypothalamic neuronal networks [39] in CAP-treated rats. In fact, a reduction in glucocorticoid levels could underlie the “healthier” endocrine and metabolic profile of the CAP rats in the present study, since removal of adrenals resulting in other studies has been shown to increase insulin sensitivity and metabolism and reduce body weight gain even in rats which have a deficient leptin signaling system [40–42].

This study shows that neonatal CAP treatment results in endocrine, metabolic, and probably neuronal adjustments which serve to maintain energy balance and glucose homeostasis in these animals. At present, we do not know whether these adjustments have occurred early in life (i.e., in the days following

CAP treatment in the neonatal stage) and whether they are perhaps not observed when CAP is applied in adult animals. In summary, neonatal CAP treatment had, in adult animals, primary inhibitory effects on plasma corticosterone levels, which could have contributed to augmented insulin action during hyperglycemia. Secondary effects on plasma adiponectin and resistin levels unlikely contributed to these effects, but could have major consequences on post-ingestive metabolism or successive fuel excursions. While these effects were correlated to increased leptin sensitivity (with food intake suppression as read-out parameter), it remains to be investigated whether increased leptin signaling is a consequence or a cause of these effects. As such, this sort of interactions might have major implications for the aetiology of obesity and diabetes because these diseases are often characterized by dysregulation of the hypothalamic–pituitary–adrenal axis [43], as well as of altered adipocyte hormone secretion and signaling [44,45].

Acknowledgment

The present study was made possible by a Career Development Award (to GvD) from the Dutch Diabetes Foundation.

References

- [1] Ahren B. Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. *Am J Physiol* 2004;286:R269–72.
- [2] Thorens B, Larsen PJ. Gut-derived signaling molecules and vagal afferents in the control of glucose and energy homeostasis. *Curr Opin Clin Nutr Metab Care* 2004;7:471–8.
- [3] Holzer P. Capsaicin as a tool for studying sensory neuron functions. *Adv Exp Med Biol* 1991;298:3–16.
- [4] Szallasi A, Blumberg PM. Vanilloid (capsaicin) receptors and mechanisms. *Pharmacol Rev* 1999;51:159–212.
- [5] Ritter RC, Ladenheim EE. Capsaicin pretreatment attenuates suppression of food intake by cholecystokinin. *Am J Physiol* 1985;248:R501–4.
- [6] Ritter RC, Ritter S, Ewart WR, Wingate DL. Capsaicin attenuates hindbrain neuron responses to circulating cholecystokinin. *Am J Physiol* 1989;257:R1162–8.
- [7] South EH, Ritter RC. Capsaicin application to central or peripheral vagal fibers attenuates CCK satiety. *Peptides* 1988;9:601–12.
- [8] Van de Wall EH, Pomp ER, Strubbe JH, Scheurink AJ, Koolaaas JM. Deafferentation affects short-term but not long-term control of food intake. *Physiol Behav* 2005;84(4):659–67.
- [9] Cui J, Himms-Hagen J. Long-term decrease in body fat and in brown adipose tissue in capsaicin-desensitized rats. *Am J Physiol* 1992;262:R568–73.
- [10] Melnyk A, Himms-Hagen J. Resistance to aging-associated obesity in capsaicin-desensitized rats one year after treatment. *Obes Res* 1995;3:337–44.
- [11] Koopmans SJ, Leighton B, DeFronzo RA. Neonatal de-afferentation of capsaicin-sensitive sensory nerves increases in vivo insulin sensitivity in conscious adult rats. *Diabetologia* 1998;41:813–20.
- [12] van Dijk G, de Vries K, Benthem L, Nyakas C, Buwalda B, Scheurink AJ. Neuroendocrinology of insulin resistance: metabolic and endocrine aspects of adiposity. *Eur J Pharmacol* 2003;480:31–42.
- [13] Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. *Nature* 1997;385:165–8.
- [14] Seeley RJ, Yagaloff KA, Fisher SL, Burn P, Thiele TE, van Dijk G, et al. Melanocortin receptors in leptin effects. *Nature* 1997;390:349.
- [15] Steffens AB. A method for frequent sampling of blood and continuous infusions of fluids in the rat without disturbing the animals. *Physiol Behav* 1969;4:833–6.

- [16] Szekely M. The vagus nerve in thermoregulation and energy metabolism. *Auton Neurosci* 2000;85:26–38.
- [17] Van de Wall EH, Gram DX, Strubbe JH, Scheurink AJ, Koolhaas JM. Ablation of capsaicin-sensitive nerves affects insulin response during an intravenous glucose tolerance test. *Li Sci* 2005;77(11):1283–93.
- [18] Shikado F, Miyasaka K, Funakoshi A, Kitani K. Necessity of hyperglycemia for effects of endogenous cholecystokinin on insulin and pancreatic exocrine secretion in conscious rats. *Jpn J Physiol* 1990;40:383–91.
- [19] Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. *Diabetes* 2004;53(Suppl 1):S143–51.
- [20] Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. *Clin Sci (Lond)* 1999;96:513–23.
- [21] Steppan CM, Lazar MA. The current biology of resistin. *J Intern Med* 2004;255:439–47.
- [22] Boden G. Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes. *Exp Clin Endocrinol Diabetes* 2003;111:121–4.
- [23] Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. *Eur J Clin Invest* 2002;32(Suppl 3):14–23.
- [24] Kamilaris TC, Johnson EO, Calogero AE, Kalogeras KT, Bernardini R, Chrousos GP, et al. Cholecystokinin-octapeptide stimulates hypothalamic–pituitary–adrenal function in rats: role of corticotropin-releasing hormone. *Endocrinology* 1992;130:1764–74.
- [25] Fallo F, Scarda A, Sonino N, Paoletta A, Boscaro M, Pagano C, et al. Effect of glucocorticoids on adiponectin: a study in healthy subjects and in Cushing's syndrome. *Eur J Endocrinol* 2004;150:339–44.
- [26] Makimura H, Mizuno TM, Bergen H, Mobbs CV. Adiponectin is stimulated by adrenalectomy in *ob/ob* mice and is highly correlated with resistin mRNA. *Am J Physiol* 2002;283:E1266–71.
- [27] Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. *Nat Med* 2002;8:731–7.
- [28] Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. *Nat Med* 2002;8:1288–95.
- [29] Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. *Nature* 2001;409:307–12.
- [30] Spiridonov VK, Vorobeva NF. The effects of stimulation and lesioning of afferent nerves on blood glucose and free fatty acid contents in rats in conditions of changing glycemia. *Neurosci Behav Physiol* 2000;30:207–11.
- [31] Nakahara I, Matsuhisa M, Shiba Y, Kuroda A, Nakatani Y, Hatazaki M, et al. Acute elevation of free fatty acids impairs hepatic glucose uptake in conscious rats. *Diabetes Res Clin Pract* 2004;66:109–18.
- [32] Peters JH, Karpel AB, Ritter RC, Simasko SM. Cooperative activation of cultured vagal afferent neurons by leptin and cholecystokinin. *Endocrinology* 2004;145:3652–7.
- [33] Wang L, Barachina MD, Martinez V, Wei JY, Tache Y. Synergistic interaction between CCK and leptin to regulate food intake. *Regul Pept* 2000;92:79–85.
- [34] Peters JH, McKay BM, Simasko SM, Ritter RC. Leptin-induced satiation mediated by abdominal vagal afferents. *Am J Physiol* 2004;288(4):R879–84.
- [35] van Dijk G. The role of leptin in the regulation of energy balance and adiposity. *J Neuroendocrinol* 2001;13:913–21.
- [36] al-Barazanji KA, Buckingham RE, Arch JR, Haynes A, Mossakowska DE, McBay DL, et al. Effects of intracerebroventricular infusion of leptin in obese Zucker rats. *Obes Res* 1997;5:387–94.
- [37] Asensio C, Cettour-Rose P, Theander-Carrillo C, Rohner-Jeanrenaud F, Muzzin P. Changes in glycemia by leptin administration or high-fat feeding in rodent models of obesity/type 2 diabetes suggest a link between resistin expression and control of glucose homeostasis. *Endocrinology* 2004;145:2206–13.
- [38] Zhang Y, Matheny M, Zolotukhin S, Tumer N, Scarpance PJ. Regulation of adiponectin and leptin gene expression in white and brown adipose tissues: influence of beta3-adrenergic agonists, retinoic acid, leptin and fasting. *Biochim Biophys Acta* 2002;1584:115–22.
- [39] Drazen DL, Wortman MD, Schwartz MW, Clegg DJ, van Dijk G, Woods SC, et al. Adrenalectomy alters the sensitivity of the central nervous system melanocortin system. *Diabetes* 2003;52(12):2928–34.
- [40] Castonguay TW, Dallman MF, Stern JS. Some metabolic and behavioral effects of adrenalectomy on obese Zucker rats. *Am J Physiol* 1986;251:R923–33.
- [41] Duclos M, Timofeeva E, Michel C, Richard D. Corticosterone-dependent metabolic and neuroendocrine abnormalities in obese Zucker rats in relation to feeding. *Am J Physiol* 2005;288:E254–66.
- [42] Freedman MR, Stern JS, Reaven GM, Mondon CE. Effect of adrenalectomy on in vivo glucose metabolism in insulin resistant Zucker obese rats. *Horm Metab Res* 1986;18:296–8.
- [43] Chan O, Inouye K, Riddell MC, Vranic M, Matthews SG. Diabetes and the hypothalamo–pituitary–adrenal (HPA) axis. *Minerva Endocrinol* 2003;28:87–102.
- [44] Gil-Campos M, Canete R, Gil A. Hormones regulating lipid metabolism and plasma lipids in childhood obesity. *Int J Obes Relat Metab Disord* 2004;28(Suppl 3):S75–80.
- [45] Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. *Clin Chem* 2004;50:1511–25.